MindMed Announces New Employee Inducement Grants
Mind Medicine Inc Ordinary Shares MNMD
News
MindMed to Participate in September Investor Conferences
MindMed readying Phase III trials for LSD therapy to treat anxiety
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
Psychedelic-medicine stocks drop after ecstasy's rocky day at the FDA
MindMed's stock soars 51.5% after FDA grants breakthrough designation to LSD therapy for a form of anxiety
Why one backer of MDMA therapy sees 'exponential' growth following FDA approval this year
MindMed's stock boosted by positive data in trial of LSD as treatment for anxiety disorder
United States